Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study

Autor: d'Erasmo, Laura, Steward, Kim, Cefalù, Angelo Baldassare, Di Costanzo, Alessia, Boersma, Eric, Bini, Simone, Arca, Marcello, van Lennep, Jeanine Roeters, Antonina Giammanco, Maurizio Averna, Gabriella Iannuzzo, Giuliana Fortunato, Marco Gentile, Arturo Puja, Tiziana Montalcini, Chiara Pavanello, Laura Calabresi, Giovanni Battista Vigna, Marco Bucci, Katia Bonomo, Fabio Nota, Tiziana Sampietro, Francesco Sbrana, Patrizia Suppressa, Carlo Sabbà, Fabio Fimiani, Arturo Cesaro, Paolo Calabrò, Fulvio Ventura, Sergio D’Addato, Livia Pisciotta, Stefano Bertolini, Genovefa Kolovou, Evangelos Liberopoulos, Eugene Daphnis, Joost Rutten, Anja Vogt, Jaimini Cegla, Shahenaz Walji, Meral Kayikcioglu, José Real, Sergio Martínez-Hervás, Avishay Ellis, Karin Littmann

Publikováno v: European Journal of Preventive Cardiology. SAGE Publications Ltd
European Journal of Preventive Cardiology, 29(5), 832-841. SAGE Publications Ltd

Aims Lomitapide is a lipid-lowering agent indicated as an adjunct therapy for adult homozygous familial hypercholesterolaemia (HoFH). This study evaluated the medium-term effectiveness and safety of lomitapide in a large cohort of HoFH patients in Eu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b4e5a3529b5b1b0118d231da6d97b6e
http://hdl.handle.net/11588/885541